We develop new
treatments for central
nervous system disorders.

We develop new
treatments for central
nervous system disorders.

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Horizon Technology Finance and Emalex Biosciences Announce $15 Million Venture Loan Facility

June 3, 2020
– Biopharmaceutical company advancing clinical research evaluating novel treatment for Tourette syndrome and childhood-onset fluency disorder – Farmington, Connecticut & Chicago, Illinois – June 3, 2020 – Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form ... Read more
Read More →

UC-Riverside: “Ecopipam reduces stuttering symptoms in proof-of-concept trial”

September 3, 2019
According to reporting by Iqbal Pittalwala at the University of California, Riverside, a team led by a UC-Riverside psychiatrist “has tested the orally administered investigational medication ecopipam on adults who stutter in an open-label, uncontrolled clinical trial and found that it reduced their stuttering symptoms ... Read more
Read More →

Emalex Biosciences Receives FDA Fast Track Designation for Ecopipam for the Treatment of Patients with Tourette Syndrome

August 28, 2019
(CHICAGO, August 28, 2019) – Emalex Biosciences, Inc. (Emalex), a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that it has received Fast Track designation for its investigational product, ecopipam, from the U.S. Food and Drug Administration (FDA) for ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy 

By emalexadmin | April 29, 2026
— Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.  — The late‑stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and supports both near‑ and long‑term growth.  — Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy 

By emalexadmin | April 29, 2026
— Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.  — The late‑stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and supports both near‑ and long‑term growth.  — Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up ... Read more
Read More →

Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation

By emalexadmin | April 13, 2026
Novel composition-of-matter patent supports formulation innovation as development advances and patient access expand CHICAGO — April 9, 2026 —Emalex Biosciences today announced that the U.S. Patent and Trademark Office issued a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 receptor ... Read more
Read More →